Vol.23 No.1

Case Report

Atypical severe central serous chorioretinopathy in a patient with systemic lupus erythematosus improved with a rapid reduction in glucocorticoid

Authors

Hiroe Sato1,2 , Satoshi Ito2 , Shingo Nagai3 , Akira Murasawa2 , Yoko Wada1 , Shuichi Murakami1 , Takeshi Kuroda1 , Masaaki Nakano4 , Ichiei Narita1

  • Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuoku, Niigata, Niigata, 951-8510, Japan
  • Department of Rheumatology, Niigata Rheumatic Center, 1-2-8 Honcho, Shibata, Niigata, 957-0054, Japan
  • Department of ophthalmology, Shibata Hospital, 1-2-8 Honcho, Shibata, Niigata, 957-0054, Japan
  • Medical Laboratory Science, School of Health Sciences, Faculty of Medicine Niigata University, 2-746 Asahimachi-Dori, Chuoku, Niigata, Niigata, 951-8510, Japan
Received:

17 January 2012

Accepted:

5 March 2012

Published online:

25 March 2012

Full Text

PDF　(member's only)

Abstract

A 36-year-old woman was diagnosed with systemic lupus erythematosus (SLE). Seven days after beginning glucocorticoid treatment, she developed reduced visual acuity, and atypical severe central serous chorioretinopathy (CSC) was confirmed. Since glucocorticoid use is an important risk factor for CSC, the PSL was reduced, tacrolimus was added, and the visual acuity improved rapidly. Reduction in glucocorticoid combined with the use of immunosuppressive agents is one option for preventing a deterioration in atypical severe CSC while still controlling SLE.

Key words

Systemic lupus erythematosus - Central serous chorioretinopathy - Glucocorticoid - Tacrolimus